RecruitingPhase NA

Effects of GLP-1 Formula on GLP-1 and Glucose Regulation

Exploring the Effects of GLP-1 Formula on GLP-1 Secretion and Postprandial Glucose Regulation

Lead sponsor

Shih Chien Huang

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Estimated enrollment

100

Study population

Obesity / overweight

Eligibility highlights

Primary endpoints

•Plasma GLP-1 concentration (pmol/L)•Blood glucose concentration (mg/dL)•Serum insulin concentration (μIU/mL)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07082062

Org study IDCS2-24173

Timeline

Milestones

Study start2025-06-02actual

Study first posted2025-07-24actual

Last update posted2025-07-24actual

Primary completion2025-10-31estimated

Study completion2025-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female participants aged 18-50 years with a body fat percentage greater than 25%.

Exclusion criteria

•Use of probiotics, weight loss products, or gastrointestinal health-related supplements or medications within the past month.

•Presence of diabetes, autoimmune diseases, cancer, chronic gastrointestinal disorders, lactose intolerance, or chronic diarrhea.

•History of gastrointestinal surgery.

•Pregnant or breastfeeding women.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

Blood glucose concentration (mg/dL)

Time frame:Day 1 and Day 7

concentration, descriptive

Primary/protocol endpoint

Serum insulin concentration (μIU/mL)

Time frame:Day 1 and Day 7

concentration, descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Plasma GLP-1 concentration (pmol/L)

Time frame:Day 1 and Day 7

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.